| Jul 11 |
Is Viking Therapeutics Stock Running Out of Steam?
|
| Jul 10 |
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
|
| Jul 9 |
Viking Therapeutics: Potential Winner In Competitive Obesity Drug Race
|
| Jul 8 |
3 Overlooked Giants-in-the-Making for Patient Investors
|
| Jul 6 |
Small, mid-size biotechs could see M&A action in H2 - PwC
|
| Jul 5 |
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
|
| Jul 3 |
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
|
| Jul 3 |
3 Biotech Moonshots With Imminent Catalyst Potential
|
| Jul 2 |
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
|
| Jul 1 |
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
|
